The Diagnostic Blind Spot: How CJD Gets Mistaken for Other Brain Diseases and What You Can Do About It

For many families, the path to a Creutzfeldt-Jakob disease diagnosis is not a straight line. It is a winding, often agonizing journey through a series of incorrect or incomplete explanations — each one delaying the specialized care that patients urgently need. At Newark CJD Center, we hear versions of the same story repeatedly: a loved one begins showing signs of rapid cognitive decline, and the first physician assumes it is Alzheimer's disease. A second specialist suspects Parkinson's. A third orders tests for autoimmune encephalitis. Months pass. Symptoms worsen. And somewhere in that fog, the real culprit — a prion disease — goes unnamed.

Understanding why this happens, and learning how to respond when it does, is one of the most powerful forms of patient advocacy available to families navigating this devastating illness.

Why CJD Is So Easily Confused With Other Conditions

CJD is a rare prion disease that causes the brain to deteriorate rapidly. Its early symptoms — memory loss, personality changes, difficulty with coordination, and visual disturbances — overlap substantially with far more common neurological conditions. Alzheimer's disease, frontotemporal dementia, Lewy body dementia, Parkinson's disease, and autoimmune encephalitis can all present with similar initial findings. Because physicians are statistically far more likely to encounter those conditions than CJD, which affects roughly one to two people per million annually in the United States, prion disease often does not appear on the differential diagnosis early enough.

The speed of progression is one of CJD's most distinguishing features, yet it is frequently misread. A patient who deteriorates noticeably over weeks rather than years should, in theory, prompt clinicians to reconsider a standard dementia diagnosis. In practice, however, the rarity of CJD means that many general neurologists — particularly those outside of academic medical centers — may not recognize this velocity as a warning signal.

Additionally, some diagnostic tools that would support a CJD diagnosis are not part of standard neurological workups. Tests such as cerebrospinal fluid analysis for the 14-3-3 protein, real-time quaking-induced conversion (RT-QuIC) assay, and specialized MRI sequences including diffusion-weighted imaging require deliberate ordering by a clinician who already suspects prion disease. Without that suspicion, those tests are never requested.

Case Illustrations: When the Diagnosis Came Too Late

Consider a scenario familiar to many families: a 62-year-old woman in the mid-Atlantic region begins forgetting appointments and stumbling when she walks. Her primary care physician refers her to a neurologist, who diagnoses early-onset Alzheimer's disease and initiates standard memory care protocols. Over the next six weeks, her condition deteriorates at an alarming rate. She develops myoclonus — involuntary muscle jerks — and her speech becomes fragmented. Only after a second neurologist is consulted does the team order a lumbar puncture and an MRI with diffusion-weighted imaging. The results are consistent with sporadic CJD. Nearly three months have elapsed since her first appointment.

In another representative case, a 58-year-old man presents with visual disturbances and gait instability. His initial diagnosis is Parkinson's disease with atypical features. His family, noting how unusually fast his condition is changing, requests a second opinion. The consulting physician at an academic center recognizes the pattern and orders RT-QuIC testing, which returns positive. The family, though devastated, is now able to engage hospice services and participate in a research registry — steps that provide both comfort and scientific value.

These scenarios are not outliers. They represent a systemic gap in how rare diseases are integrated into standard neurological practice.

Red Flags That Should Trigger CJD Testing

Not every case of cognitive decline warrants prion disease testing. But certain combinations of features should prompt a clinician — and a well-informed family — to raise the question directly. Be alert to the following:

• Rapid cognitive decline over weeks to a few months, rather than the gradual progression typical of Alzheimer's or vascular dementia
• Myoclonus, or sudden, brief muscle jerks, particularly in the context of dementia
• Visual symptoms such as double vision, blurring, or hallucinations appearing alongside cognitive changes
• Cerebellar signs including balance problems and unsteady gait that worsen quickly
• Psychiatric symptoms — anxiety, depression, or personality changes — that precede obvious neurological findings
• A family history of prion disease, which may suggest a genetic variant such as Gerstmann-Sträussler-Scheinker syndrome or fatal familial insomnia
• Age of onset in the 50s or 60s, which is younger than typical Alzheimer's disease

If several of these features are present simultaneously, the case warrants a thorough discussion about CJD testing, regardless of how unlikely it may seem statistically.

Questions to Ask Your Medical Team

Advocating for a correct diagnosis requires preparation. When meeting with a neurologist, consider asking the following:

1. "Have you considered prion disease in the differential diagnosis, and if not, why not?" This question opens the door without being confrontational and signals that the family is informed.
2. "Given the speed of decline, what conditions other than Alzheimer's or Parkinson's could explain this presentation?" Rapid progression is a key distinguishing feature that deserves explicit discussion.
3. "Has an MRI been ordered with diffusion-weighted imaging sequences specifically?" Standard MRI protocols may miss the cortical ribboning and basal ganglia changes associated with CJD.
4. "Would a cerebrospinal fluid analysis including RT-QuIC testing be appropriate here?" RT-QuIC has high sensitivity and specificity for CJD and is available at several reference laboratories in the United States.
5. "Can you refer us to a neurologist at an academic medical center who has experience with rare dementias?" This is a reasonable and appropriate request, not an insult to the treating physician.

How to Pursue a Second Opinion

Seeking a second opinion is not a betrayal of your physician — it is a standard and respected part of managing a serious or uncertain diagnosis. When symptoms do not fit a tidy narrative, or when a patient's condition is deteriorating faster than the diagnosis would predict, a second set of expert eyes is not just reasonable; it is essential.

Start by requesting copies of all imaging, lab results, and clinical notes. Academic medical centers with dedicated prion disease or rare dementia programs — including centers affiliated with the National Prion Disease Pathology Surveillance Center — are well-positioned to evaluate complex cases. When scheduling the consultation, be explicit with the intake team that CJD is a concern you want addressed.

At Newark CJD Center, our team is committed to supporting families through exactly this kind of diagnostic uncertainty. Whether you are seeking guidance on which questions to ask, assistance navigating the referral process, or simply a knowledgeable voice to help you interpret what you are hearing, we are here. The stakes are too high for any family to face this process alone — and the right diagnosis, even a difficult one, is always better than the wrong one.